4.7 Article

No evidence for brain renin-angiotensin system activation during DOCA-salt hypertension

Journal

CLINICAL SCIENCE
Volume 135, Issue 2, Pages 259-274

Publisher

PORTLAND PRESS LTD
DOI: 10.1042/CS20201239

Keywords

-

Funding

  1. Alnylam Pharmaceuticals
  2. National Health and Medical Research Council of Australia CJ Martin Fellowship [1112125]
  3. National Natural Science Foundation of China [81900668]
  4. National Health and Medical Research Council of Australia [1112125] Funding Source: NHMRC

Ask authors/readers for more resources

The study found that brain angiotensin II depends on circulating angiotensinogen in DOCA-salt hypertension model. Spironolactone normalized blood pressure, restored brain angiotensin II, and lowered blood pressure, indicating that DOCA-salt hypertension is not mediated by brain RAS activation.
Brain renin-angiotensin system (RAS) activation is thought to mediate deoxycorticosterone acetate (DOCA)-salt hypertension, an animal model for human primary hyperaldosteronism. Here, we determined whether brainstem angiotensin II is generated from locally synthesized angiotensinogen and mediates DOCA-salt hypertension. To this end, chronic DOCA-salt-hypertensive rats were treated with liver-directed siRNA targeted to angiotensinogen, the angiotensin II type 1 receptor antagonist valsartan, or the mineralocorticoid receptor antagonist spironolactone (n = 6-8/group). We quantified circulating angiotensinogen and renin by enzyme-kinetic assay, tissue angiotensinogen by Western blotting, and angiotensin metabolites by LC-MS/MS. In rats without DOCA-salt, circulating angiotensin II was detected in all rats, whereas brainstem angiotensin II was detected in 5 out of 7 rats. DOCA-salt increased mean arterial pressure by 19 +- 1 mmHg and suppressed circulating renin and angiotensin II by 90%, while brainstem angiotensin II became undetectable in 5 out of 7 rats (<6 fmol/g). Gene silencing of liver angiotensinogen using siRNA lowered circulating angiotensinogen by 97 +- 0.3%, and made brainstem angiotensin II undetectable in all rats (P<0.05 vs. non-DOCA-salt), although brainstem angiotensinogen remained intact. As expected for this model, neither siRNA nor valsartan attenuated the hypertensive response to DOCA-salt, whereas spironolactone normalized blood pressure and restored brain angiotensin II together with circulating renin and angiotensin II. In conclusion, despite local synthesis of angiotensinogen in the brain, brain angiotensin II depended on circulating angiotensinogen. That DOCA-salt suppressed circulating and brain angiotensin II in parallel, while spironolactone simultaneously increased brain angiotensin II and lowered blood pressure, indicates that DOCA-salt hypertension is not mediated by brain RAS activation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available